title: Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats.
abstract: OBJECTIVE
  To evaluate the effificacy of dual antiplatelet therapy combined with Naoxintong Capsule ([see text], NXTC) in a rat model of coronary microembolization (CME).
  
  
  METHODS
  A total of 95 rats were randomly divided into 6 groups: control, sham-operation, CME model, NXTC, dual antiplatelet (clopidogrel and aspirin) intervention (DA), and NXTC combined with DA (NDA) groups. The complete data in 69 rats were obtained. The number of CME, myocardial apoptosis rate, bleeding time, clotting time, and adensosine diphosphate (ADP)-induced platelet aggregation were assessed.
  
  
  RESULTS
  Compared with the CME group, the number of CME and myocardial apoptosis rates were signifificantly decreased in the NXTC, DA, and NDA groups (P <0.01). Compared with other intervention groups, the number of CME and myocardial apoptosis rates were the least in the NDA group (P <0.01), and the incidence of surgical bleeding was the highest in the DA group (P <0.01). Compared with the CME group, ADP-induced maximum platelet aggregation rate was significantly inhibited in the NXTC, DA, and NDA groups (P <0.01), both bleeding time and clotting time were signifificantly increased in the NXTC, DA, and NDA groups (P <0.01), while the above parameters were the highest in the DA group (P <0.05).
  
  
  CONCLUSIONS
  The combination therapy of NXTC and DA enhanced the anti-CME effect of either therapy alone and reduced the risk of the DA therapy-associated bleeding, demonstrating an improved benefifit/ risk ratio in the rat model of CME.
authors.affiliation: Fujian Provincial Cardiovascular Disease Institute, Provincial Clinical College of Fujian Medical University, Fuzhou, China.
authors.forename: Huan
authors.initials: H
authors.lastname: Wang
authors.forename: Wen-juan
authors.initials: WJ
authors.lastname: Zhong
authors.forename: Ming-wei
authors.initials: MW
authors.lastname: Huang
authors.forename: Xiao-ying
authors.initials: XY
authors.lastname: Wu
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D016063:Blood Loss, Surgical / Q000503:physiopathology; D002214:Capsules; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D004617:Embolism / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009206:Myocardium / Q000473:pathology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016019:Survival Analysis; D013927:Thrombosis / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D010975:Platelet Aggregation Inhibitors; C571443:naoxintong